From Yahoo Finance: 2025-05-22 10:57:00

Paratek Pharmaceuticals has acquired Optinose for nearly $330 million, expanding its product offerings with Nuzyra and Xhance. The merger agreement was signed in March 2025, with shareholders approving the deal in May. The acquisition includes all outstanding shares and debt assumption, supported by capital from Paratek, Novo Holdings, and B-FLEXION Life Sciences.

Shareholders received $9 per share in cash and contingent value rights (CVRs) up to $5 per share based on Xhance’s net revenue milestones. Nuzyra fights tetracycline resistance and treats bacterial pneumonia and skin infections. Xhance, a drug-device combo, delivers a topical steroid to nasal cavities. CEO Evan Loh aims to expand the portfolio through future acquisitions.

Lazard and Skadden advised Paratek, while Evercore and Hogan Lovells US advised Optinose in the acquisition. The move aligns with Paratek’s goal to become a multi-product specialty therapeutics company addressing unmet medical needs. The acquisition marks a strategic step towards future growth and expanding their product portfolio.



Read more at Yahoo Finance: Paratek expands commercial portfolio with Optinose